Please login to the form below

Not currently logged in

Lilly says insulin peglispro too risky to pursue

Discontinues development of medicine once tipped as a diabetes blockbuster


Eli Lilly has decided to discontinue development of insulin peglispro, a drug once considered a potential blockbuster for type 1 and 2 diabetes.

Insulin peglispro has been developed as a rival to Sanofi's big-selling basal insulin Lantus (insulin glargine), and last year was shown to provide improved glucose control compared to its rival in head-to-head phase III trials.

Earlier this year however the pharma company said it had decided to delay regulatory filings for the drug in the US and Europe to examine changes in liver fat seen in some patients treated in its phase III programme. 

After months of negotiation with regulatory authorities and clinical specialists, the company says it has now decided to stop the programme and divert resources to other projects in its R&D pipeline, adding it will take a $55m charge in the fourth quarter as a result.

"We know that moving forward would have required a significant amount of time and investment with no assurance that we would find conclusive answers," commented Enrique Conterno, president of Lilly's diabetes division.

"We are disappointed in the outcome … but we have an unprecedented opportunity to build upon the industry's broadest diabetes portfolio, which includes six new treatments approved since the middle of 2014," he added.

These include a biosimilar version of Lantus and fixed-dose oral combination Glyxambi (empagliflozin/linagliptin), both partnered with Boehringer Ingelheim, as well as its once-weekly GLP-1 agonist Trulicity (dulaglutide).

The basal insulin market has undergone some fairly big changes with the first Lantus biosimilars now rolling out onto the market. Meanwhile, Novo Nordisk's rival basal insulin Tresiba (insulin degludec) was approved in the US in October - after two years' delay - and Sanofi has recently launched long-acting Lantus follow-up Toujeo (insulin glargine).

Analysts have been divided on the commercial prospects for insulin peglispro, with Peak sales estimates ranged from $500m a year to more than $2bn.

Lilly was also forced to abandon development of CETP inhibitor evacetrapib - in development for atherosclerosis - in October after it failed to show efficacy in a pivotal trial.

Article by
Phil Taylor

7th December 2015

From: Research



Subscribe to our email news alerts

Featured jobs


Add my company
The Difference Collective

Welcome to the Difference Collective – a healthcare communications team of 80+ talented experts who Deliver Differently. We’re purpose-built around...

Latest intelligence

Jonathan Cooke
The fight against antimicrobial resistance
By Jonathan Cooke...
How long should my healthcare video be?
This week, Tim took a deeper look at a question we are asked almost daily; how long should my healthcare video be?...
Article: How behavioural economics can help you build better brand communications
For pharma marketers, accelerating brand performance means maximizing return on investment. Your campaigns need to trigger the right emotions, and the right actions, in your audience....